Phase II trial of streptozotocin, mitomycin‐C and 5‐fluorouracil (SMF) in the treatment of advanced pancreatic cancer

R. Glen Wiggans, Paul V. Woolley, John S. Macdonald, Tarilyn Smythe, Winston Ueno, Philip S. Schein

Research output: Contribution to journalArticlepeer-review

87 Scopus citations

Abstract

Ten of 23 patients with advanced measurable adenocarcinoma of the pancreas achieved an objective response after treatment with a regimen consisting of streptozotocin, mitomycin‐C and 5‐fluorouracil (SMF). The median duration of response is in excess of 7 months, and responding patients have lived significantly longer than patients with progressive disease (7.5+ months vs. 3 months). The SMF regimen was adequately tolerated. Principal toxicities included myelosuppression, which was generally mild, nausea and vomiting. There was reversible nephrotoxicity in the form of proteinuria in 30% of patients and persistent azotemia in 9% of patients.

Original languageEnglish (US)
Pages (from-to)387-391
Number of pages5
JournalCancer
Volume41
Issue number2
DOIs
StatePublished - Feb 1978

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II trial of streptozotocin, mitomycin‐C and 5‐fluorouracil (SMF) in the treatment of advanced pancreatic cancer'. Together they form a unique fingerprint.

Cite this